LatchBio launches Antibody Discovery Benchmark; Opus and Gemini excel, OpenAI models struggle
shensi · x · 2026-09-03
- LatchBio introduced an Antibody Discovery Benchmark testing whether AI agents can make scientific decisions across the stages of therapeutic antibody discovery.
- It comprises 100 evaluations across ten areas drawn from concrete drug programs: target and modality selection, assay design, binder discovery, binding characterization, cellular pharmacology, antibody engineering, and preclinical candidate de-risking.
- The domain is multiparameter and context-dependent: affinity must be weighed against specificity, stability, solubility, expression, and biological activity, interpreted in the context of the experimental system.
- Early results: Claude Opus and Gemini perform well, while OpenAI models generally do poorly — a surprising outcome.
More from Models
- Meta's Muse Spark 1.3 lands on OpenRouter with 1M context for agentic workflows — armand_ruiz · 2026-09-03
- DeepSeek-V4-Pro ships with 1.6T-param MoE; open-source eval harness steals the show — DeepLearningAI · 2026-09-03
- Rival AI agents: cross-vendor model review catches what self-review misses — rseroter · 2026-09-03
- Gemini's Distinctive Take on AI Sentience Turns Heads — aiamblichus · 2026-09-03
- Grok Heavy user burns through limits in 3-4 days, suspects a metering bug — Daniel_Farinax · 2026-09-03
- Reddit users report ChatGPT 5.6 suddenly got much worse: forgetful, lazy and hallucinating — Individual-Value7169 · 2026-09-03